CANCER:

Oligodendroglioma

News alerts, weekly reports and conference planners

Related cancers:

‹

›

IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	PCV Sensitive: A2 - Guideline PCV Sensitive : A2	PCV Sensitive: A2 - Guideline PCV Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2	carmustine Sensitive: A2 - Guideline carmustine Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	PCV Sensitive: A2 - Guideline PCV Sensitive : A2	PCV Sensitive: A2 - Guideline PCV Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion	Oligodendroglioma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion	Oligodendroglioma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion	Oligodendroglioma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion	Oligodendroglioma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q) + BRAF V600E	Oligodendroglioma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion	Oligodendroglioma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion	Oligodendroglioma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK3 fusion	Oligodendroglioma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK2 fusion	Oligodendroglioma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion	Oligodendroglioma	IDH1 mutation + Chr del(1p) + Chr del(19q) + NTRK1 fusion	Oligodendroglioma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2

Oligodendroglioma

Associations(32)

Associations
(32)